Good news for mCRPC (hopefully), phase 2

[Maxone73]

And here we go:

"mCRPC patients who have relapsed or are refractory to androgen receptor signalling inhibitors (ARSIs) such as apalutamide, darolutamide, abiraterone and enzalutamide are included in the study."

clinicaltrialsarena.com/new...

[Mw921000000]

the great joy that I feel reading about another possible treatment for mCRPC is unexplainable 🙏🏻. We were just told about the DORA trial conducted at MSK which combines taxotere with RAD-223. There’s not much explained about it in the sites I’ve found about it, but I’ll link it in case you’re interested. It’s already in phase III.

clinicaltrials.gov/study/NC...

[Maxone73 in reply to Mw921000000]

let's hope for the best....

by the end of the month we will know more about arx517 (I hate when they wait for a major international conference to make some data public but...that's how it is) and they will talk also about data from phase 1 of urologytimes.com/view/phase...

I would also bet on some other "new" approaches, like oncolytic viruses....

[Tall_Allen]

Good luck! I hope AR degraders work.

[Maxone73]

I still don’t need them but I like to know my options

[gsun]

Possibly another arrow in the quiver. It's a long way away.

[j-o-h-n]

Let's hope for the best, and pray for hope....

Good Luck, Good Health and Good Humor.

j-o-h-n Sunday 10/08/2023 6:16 PM DST

[Hidden]

My husband is entering an ARX517 trial. He is scheduled for all the prep scans 17th and 18th, and provided his scans meet the trial standards, he will start ARX517 shortly thereafter. I am hoping PSMA and GRPr (or another) targeted drug will be the future dual therapies to keep MCRPC in check. 🤗

[Maxone73 in reply to Hidden]

I truly hope that arx517 will do wonders, for him and also for us all! 🤗